Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show…
Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…
Achievement reflects the dedication of surgeons and care teams worldwide to improving patient outcomes through use of Intuitive’s minimally invasive…
Newark, DE, Dec. 29, 2025 (GLOBE NEWSWIRE) -- The term "best" reflects common consumer search phrasing and is used here…
Mexico: The New Hub for US Hair Transplants December 26, 2025 10:00 ET | Source: Capilea Mexico Tijuana, BC, Dec.…
PYLCLARI® provides solutions to a wider patient group across Poland where there is high demand and unmet need PARIS, Dec.…
- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain…
In addition, the expansive elacestrant clinical development program updates reinforce its potential as a backbone endocrine therapy in combination settings, as…
93% overall response and 76% complete response rates with median progression-free survival of 18 months in patients with large B-cell…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…